# A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

> **NCT01305252** · PHASE4 · COMPLETED · sponsor: **Stanford University** · enrollment: 21 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** treprostinil inhalations
- **DRUG:** tadalafil

## Key facts

- **NCT ID:** NCT01305252
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01305252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01305252, "A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01305252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*